Crescita Therapeutics Inc (CTX) — Cash Flow-to-Debt Ratio
Crescita Therapeutics Inc (CTX) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of CA$416.00K could theoretically repay 0% of its total liabilities (CA$4.75 Million) in one year. See how financially flexible is Crescita Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crescita Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Crescita Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Crescita Therapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Crescita Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Crescita Therapeutics Inc. Check Crescita Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CA$1.07 Million | CA$4.75 Million | ▼ -50.7% |
| 2024 | 0.46x | CA$2.73 Million | CA$5.95 Million | ▲ +27.5% |
| 2023 | 0.36x | CA$2.08 Million | CA$5.78 Million | ▲ +360.3% |
| 2022 | -0.14x | CA$-1.02 Million | CA$7.39 Million | ▲ +27.4% |
| 2021 | -0.19x | CA$-1.60 Million | CA$8.40 Million | ▼ -119.3% |
| 2020 | 0.98x | CA$5.61 Million | CA$5.70 Million | ▲ +6.3% |
| 2019 | 0.93x | CA$5.31 Million | CA$5.73 Million | ▲ +636.3% |
| 2018 | -0.17x | CA$-1.48 Million | CA$8.56 Million | ▲ +77.9% |
| 2017 | -0.78x | CA$-7.40 Million | CA$9.46 Million | ▲ +31.7% |
| 2016 | -1.15x | CA$-18.58 Million | CA$16.21 Million | ▲ +62.5% |
| 2015 | -3.06x | CA$-13.92 Million | CA$4.55 Million | ▼ -22.8% |
| 2014 | -2.49x | CA$-9.30 Million | CA$3.74 Million | — |